Bluestein R H & Co. lifted its holdings in Henry Schein, Inc. (NASDAQ:HSIC) by 16.4% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 143,486 shares of the company’s stock after acquiring an additional 20,262 shares during the quarter. Bluestein R H & Co. owned 0.18% of Henry Schein worth $26,261,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in HSIC. BlackRock Inc. lifted its holdings in shares of Henry Schein by 2,999.6% in the 1st quarter. BlackRock Inc. now owns 5,595,279 shares of the company’s stock worth $951,028,000 after acquiring an additional 5,414,761 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new stake in Henry Schein during the 1st quarter valued at $50,281,000. Marshall Wace North America L.P. bought a new stake in Henry Schein during the 1st quarter valued at $50,281,000. Vanguard Group Inc. raised its holdings in Henry Schein by 3.0% during the 2nd quarter. Vanguard Group Inc. now owns 8,086,317 shares of the company’s stock valued at $1,479,959,000 after buying an additional 236,862 shares during the last quarter. Finally, PGGM Investments bought a new stake in Henry Schein during the 2nd quarter valued at $32,623,000. Hedge funds and other institutional investors own 89.05% of the company’s stock.

A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Henry Schein from a “buy” rating to a “hold” rating in a report on Friday, June 23rd. Stifel Nicolaus reiterated a “hold” rating on shares of Henry Schein in a report on Thursday, July 6th. BidaskClub lowered shares of Henry Schein from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Piper Jaffray Companies upgraded shares of Henry Schein from a “neutral” rating to an “overweight” rating in a report on Friday, September 15th. Finally, UBS AG reiterated a “buy” rating on shares of Henry Schein in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $92.85.

TRADEMARK VIOLATION NOTICE: “Bluestein R H & Co. Acquires 20,262 Shares of Henry Schein, Inc. (HSIC)” was originally reported by Daily Political and is owned by of Daily Political. If you are reading this story on another website, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/22/bluestein-r-h-co-acquires-20262-shares-of-henry-schein-inc-hsic.html.

Shares of Henry Schein, Inc. (NASDAQ:HSIC) traded down 0.28% on Friday, reaching $79.10. 551,303 shares of the company’s stock traded hands. Henry Schein, Inc. has a 12-month low of $73.11 and a 12-month high of $93.50. The stock has a 50-day moving average of $85.78 and a 200 day moving average of $88.02. The firm has a market cap of $6.25 billion, a P/E ratio of 11.56 and a beta of 1.10.

Henry Schein (NASDAQ:HSIC) last released its earnings results on Tuesday, August 8th. The company reported $0.88 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.02. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The business had revenue of $3.06 billion during the quarter, compared to the consensus estimate of $3.05 billion. During the same period last year, the company earned $0.82 earnings per share. The business’s revenue for the quarter was up 6.4% compared to the same quarter last year. On average, equities research analysts expect that Henry Schein, Inc. will post $3.64 earnings per share for the current year.

Henry Schein announced that its board has authorized a stock repurchase program on Monday, September 18th that allows the company to buyback $400.00 million in shares. This buyback authorization allows the company to purchase up to 6.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its shares are undervalued.

In other news, SVP Paul Rose sold 2,126 shares of Henry Schein stock in a transaction on Wednesday, September 6th. The stock was sold at an average price of $172.51, for a total transaction of $366,756.26. Following the completion of the sale, the senior vice president now directly owns 17,841 shares in the company, valued at $3,077,750.91. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.27% of the stock is currently owned by company insiders.

Henry Schein Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Want to see what other hedge funds are holding HSIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Henry Schein, Inc. (NASDAQ:HSIC).

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related companies with MarketBeat.com's FREE daily email newsletter.